Biophytis has Filed with the French National Authority for Health (HAS) an Application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19
Portfolio Pulse from Benzinga Newsdesk
Biophytis has filed an application for Early Access Authorisation (EAA) with the French National Authority for Health (HAS) for Sarconeos (BIO101) in the treatment of severe forms of COVID-19. The application was filed through its pharmaceutical partner Intsel Chimos.
May 26, 2023 | 7:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biophytis has filed for EAA with the French National Authority for Health for Sarconeos (BIO101) in the treatment of severe COVID-19 cases, potentially boosting its stock.
The filing for Early Access Authorisation for Sarconeos (BIO101) in the treatment of severe COVID-19 cases is a significant development for Biophytis. If approved, it could lead to increased demand for the treatment and potentially boost the company's stock price. The news is highly relevant to Biophytis and important for investors, as it could have a positive impact on the company's financial performance and stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100